Since 2016, afamelanotide, a potent α-melanocyte-stimulating hormone (α-MSH) synthetic analogue that increases the production of eumelanin by agonistically binding to the melanocortin-1 receptor (MC1R), has been available for the treatment of adult patients with EPP (7). This evidence concerns the gene MC1R and autosomal erythropoietic protoporphyria.